|
Published by: Global Markets Direct
Published: Jul. 31, 2012 - 46 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- HIV-Associated Lipodystrophy Syndrome Overview
- Therapeutics Development
- An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome
- HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies
- HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Products under Development by Companies
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development
- Theratechnologies Inc.
- HIV-Associated Lipodystrophy Syndrome – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Egrifta - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Serostim - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Avandia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant Human Growth Hormone + Avandia - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Leptin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Recombinant IGF-I - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Drug Profile Updates
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Discontinued Products
- HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products
- HIV-Associated Lipodystrophy Syndrome – Product Development Milestones
- Featured News & Press Releases
- Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin
- Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela
- Dec 07, 2011: Theratechnologies To Discontinue COPD Clinical Program And Accelerate Path To Profitability
- Oct 19, 2011: Theratechnologies Announces Application For Registration Of Tesamorelin In Mexico
- Aug 31, 2011: Theratechnologies Announces Marketing Authorization Application For Tesamorelin In Brazil
- Jul 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi
- Jun 06, 2011: Theratechnologies Announces Filing Of European Marketing Authorization Application For Tesamorelin
- Jun 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM
- May 27, 2010: Theratechnologies Announces Positive Vote By FDA Advisory Committee For Tesamorelin
- Mar 22, 2010: FDA Confirms Date For Advisory Committee Review Of Theratechnologies' Tesamorelin New Drug Application
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, H2 2012
- Products under Development for HIV-Associated Lipodystrophy Syndrome – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Theratechnologies Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Drug Profile Updates
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Discontinued Products
- HIV-Associated Lipodystrophy Syndrome Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, H2 2012
- Products under Development for HIV-Associated Lipodystrophy Syndrome – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHIV-Associated Lipodystrophy Syndrome – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012', provides an overview of the HIV-Associated Lipodystrophy Syndrome therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
